Chronic Venous Insufficiency: Clinical Trials

3 trials for Chronic Venous Insufficiency, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 unknown. 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 33Unknown 3

Follow Chronic Venous Insufficiency: new trials by email Literature Review of Chronic Venous Insufficiency trials Research Report on Chronic Venous Insufficiency

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Assess the Efficacy and Safety of Endolex Forte VErsus Diosmin and Hesperidin in Reducing VeNous Insufficiency
Endolex Forte®, A combination of diosmin and hesperidin - Chronic Venous Insufficiency
Phase 3UnknownSunWave Pharma1202016-11-012016-10-28
Study to Evaluate the Efficacy and Tolerability of Venaflon Use in Reducing the Symptoms Caused by Chronic Venous Insufficiency When Compared With Daflon
Daflon, Venaflon (Diosmin and Hesperidin) - Chronic Venous Insufficiency, Disease
Phase 3UnknownLaboratório Teuto Brasileiro S/A822012-02-012011-11-22
Efficacy and Tolerability of the Use of Varicell Compared With Daflon
Daflon, Varicell placebo - Chronic Venous Insufficiency, Hemorrhoids
Phase 3UnknownVidfarma Indústria de Medicamentos Ltda.1022011-07-012011-06-14

Narrower conditions

Disease (1)  ·  Hemorrhoids (1)  ·  Venous Insufficiency (1)

Broader conditions

Cardiovascular Diseases (2)  ·  Vascular Diseases (2)  ·  Digestive System Diseases (1)  ·  Gastrointestinal Diseases (1)  ·  Intestinal Diseases (1)  ·  Pathologic Processes (1)  ·  Pathological Conditions, Signs and Symptoms (1)  ·  Rectal Diseases (1)

Interventions

Diosmin (2)  ·  Hesperidin (2)  ·  Keratins (1)

Sponsors

Laboratório Teuto Brasileiro S/A (1)  ·  SunWave Pharma (1)  ·  Vidfarma Indústria de Medicamentos Ltda. (1)

Countries

Brazil (1)

Top investigators

Calin Giurcaneanu, MD (1)  ·  Jacques Waisberg, Investigator (1)